

# **Radiobiological characterization of clinical proton and carbon-ion beams :**

John Gueulette

Vincent Grégoire

Pierre Scalliet

*Université catholique de Louvain, Brussels, Belgium*

# Improvement of radiotherapy

## ■ Ballistic selectivity


Increasing the dose to the tumor while reducing the dose to the surrounding normal tissues

## ■ Differential effect


Compared to conventional radiations the effect is relatively more marked on the tumour than on the normal tissues (RBE)

# What is the biological effect of ionising radiation?

There are several arguments pointing at the DNA as the main target of ionising radiation




# Ionisations along an electron track (secondary electron after low LET irradiation)




# Sequence of events


- Energy deposits (primary and secondary electrons)
- DNA damage.
- DNA re-arrangement.
- Repair induction (enzyme synthesis).
- Cell cycle arrest.
- Repair vs. apoptosis.
- Cell death
- Tissue failure



# DNA is the primary target





# Various types of DNA damage





Possible  
consequence of  
DNA damage





Cell death after misrepair  
(lethal mutation)

Apoptosis

Base pairs can be substituted, or deleted, or added, all resulting in an alteration of information.

A gene can be inactivated or mutated.

A mutation can amplify or decrease the gene expression.

Normal DNA Sequence: **AGT****CGA**  
Codon 1 Codon 2

### Point Mutations:


Base Substitution: **AGT****AGA**  
Codon 1 Codon 2

### Frameshift Mutations:

Insertion: **A****TG****TCGA**  
Codon 1 Codon 2 Codon 3

Deletion: **AT****CGA**  
Codon 1 Codon 2


# A dose increment kills a fixed proportion of cells




Exponential survival curve of prokaryotes and bacteria


Poisson's law  
 $S = e^{-\alpha D}$

# Cell survival curve



Clones can be seen








# Initial part of the survival curve

A steep initial part exists on survival curves, particularly in resistant cells.

It is interpreted as a sign of repair induction when and if the damage concentration is sufficient to « trigger » repair enzyme synthesis.



# The linear quadratic model




the model of radiation action




# Ionisation along a particle track

Low density of ionisation

High density of ionisation




# Direct and indirect effects




# Protons


Protons are sparsely ionising, majority of indirect effects



# Carbon ions

Carbon ions are densely ionising, majority of direct effects







**Densely ionizing:**  
e.g.;  $\alpha$  particle, proton


**Sparsely ionizing:**  
e.g.;  $\gamma$ -ray or X-ray

Dense energy deposits, repair inefficient


Scattered energy deposits, repair efficient





Induction of repair enzymes with X-rays and carbon ions, same absorbed dose






The microscopic dose is evenly distributed over the cell nuclei for photons.



The image shows cell nuclei after X-irradiation. Repair related proteins (yellow color) show up all over the cell nucleus in an immune fluorescent image. Cell repair is normally achieved after half an hour.






**D**


← Biological knowledge →

Better Poor



H Z=1   He Z=2   Li Z=3   Be Z=4   B Z=5   C Z=6   Si Z=14   Cs Z=20   Ti Z=22   Fe Z=26


Ion



Typical mammalian cell

Track structure depends on energy and Z





# Microdosimetry





Tissue-equivalent proportional counter :


- The sphere is the cathode, in tissue equivalent material.
- The anode is central.
- The gas filling the sphere is tissue equivalent (C, N, O, H).
- Its pressure can be adjusted to simulate small volumes of tissue.
- Irradiation is delivered at extreme low dose rate.
- Electric charges are collected, proportional to the individual energy deposits.

TEPC of Rossi, Columbia University



# Microdosimetric spectra : a tool for tracking the RBE variations





Energy deposition along the diameter of a sphere of the same size as the ***vital radiosensitive structures***





# Energy of the incident particles...



## Identical nominal energy and identical nuclear reaction ...



# Depth ...




## *Summary of pertinent conclusions (1)*

- Conceptually, RBE is a measure of the biological effectiveness differences related to *radiation quality only*
- RBE is essentially **variable** and depends on numerous factors related 1) to **biology** or, 2) to the **beam delivery technique**
- **Biology** : the main sources of RBE variation are : • the **biological system** (tissue, endpoint, etc.) and • **dose, dose rate and fractionation**
- **Beam** : the main sources of RBE variation are : • **Depth** (for heavy ions), • **filtration** (for fast neutrons), • **collimation**, etc.
- RBE is correlated with ionization density. *Roughly speaking, it increases with LET.*




## *Summary of pertinent conclusions (2)*

- When determining RBEs, **all conditions** - but the radiation quality - have to be the same for the intercompared beams
- Inherent performance of the beam generators as well as practical reasons (e.g, distance) prevent from adopting **ideal** experimental procedure
- Recourse to **indirect method** for RBE determination is often required (RBE ratios)
- Recourse to **fractionated** irradiations is most of the time required to determine **RBEs for small doses**
- **Microdosimetry** is a powerful tool for **tracking** the potential RBE variations



# Proton beam (Nice)



Plateau (entry beam)


Most events are in the 1 keV/mm range, with a significant component around 10

End of Bragg peak

Most events are in the range 10-30 keV/mm range, with a significant component around 100.


Spectrum : sum of individual energy deposits

# Proton beam (Nice)




Let increases  
as the beam  
progresses  
in depth  
(SOBP)

# Density of energy deposits in the Bragg peak of carbon ions



# Linear energy transfer (LET)


- LET is the physical quantity of ionisation density; its unit is the keV/ $\mu\text{m}$ .
- The higher the LET, the broader the DNA damage and, hence, the larger the biological effect



# RBE ?


The relative biological effectiveness is a ratio of dose:

$D_{\text{lowLET}}/D_{\text{highLET}}$   
for any given level of effect



All the irradiations performed under the same conditions, e.g. :


- Irradiation in a single fraction
- Acute dose rate
- Same day (and moment in the day)
- Animals from the same population
- Randomized (dose / radiation quality)
- Same experimenters
- Reliable dosimetry
- Etc.





**RBE accounts for the *biological effectiveness difference* related **only to the *radiation quality difference*****




# Different radiation quality have different RBE's




# Oxygen effect



# Reduced effect of oxygen





# As LET increases OER decreases



*Reduction of radiosensitivity differences :*

**Potential therapeutic advantage**

**when the tumor is radioresistant  
in comparison with healthy tissues**





Potential therapeutic benefit due to the **reduction**  
of an **unfavourable** differential effect

*Reduction of radiosensitivity differences :*

**contra-indication**

**when the healthy tissues are radioresistant  
In comparison with the tumor**



Contra-indication due to the **reduction** of  
a **favourable** differential effect

**Hadron RBE is  
different than that  
of photons**

Buid-up of radiobiological  
experience and disclosure  
of potential benefits

**« Pretherapeutic »  
experiments**

**RBE varies with  
« radiation quality »**


**Safe and optimum  
clinical application**

**« Preclinical »  
experiments**

**All the beams are  
different**

Transfer of radiobiological /  
clinical information and  
coherency of treatments

**Radiobiological  
Calibration /  
Intercomparison**



Summary of in vivo data on jejunal crypt cells



RBE variations related  
to biological system

=

**Rationale for clinical  
application of high-LET  
radiations**


RBE variation related  
to radiation quality  
(energy)

=

**Emergence  
of problems  
related to :**

- **Transferring clinical and radiobiological information**
- **Pooling clinical data**
- **Optimizing clinical applications**
- **Comparing with conventional radiations**

Proton RBE relative to gamma




**Differential Effect**  
(neutrons, ions)

**NO differential effect**  
(protons)

Proton RBEs are **too small** to result  
in a ***workable* differential effect**

*Potential advantage of protons  
is essentially ballistic*



Proton RBEs are **big in comparison**  
**with dose accuracy requirements ...**

*and raise essentially  
**Bio-dosimetry questions***

Gamma Equivalent Dose =  
**physical dose x RBE**

**Uncertainties in RBE** values lead to  
**equal uncertainties** in the derived  
Gamma Equivalent Doses

The dose accuracy required in  
radiotherapy is **3.5 %**

***In vitro systems***  
**(Proton RBE = 0.94 - 1.63)**

*Substantial spread between cell lines and conflicting conclusions about :*

- RBE value in reference conditions (energy, depth)
- possible RBE increase with depth
- possible RBE increase with SF (or fractionation)

***In vitro* systems**  
**(Proton RBE = 0.94 - 1.63)**

*Possible causes of the spread of the data :*

- Dosimetry ?
- Underlying theory (model to fit the data)
- Randomization ?
- Plating efficiency ?

**Uncertainties above 20 %**

***In vivo systems***  
**Proton RBE 1.08 - 1.17**

*Limited amount of data. Present-day questions are :*

- RBE increase with fractionation ?
- RBE difference for early and late tissue tolerance ?
- RBE increase with depth ?

# Which system to use for



- calibrating
- intercomparing

# clinical proton beams ?



Systems and endpoints which result in widely different values for the RBE of neutron relative to X-rays ...

... give similar values for the **RBE differences** between two closely related neutron energies





*Consequently, the choice  
of a biological system for  
intercomparisons should be governed  
largely by its*


- ***portability,***
- ***repeatability***
- ***and convenience.***

# Intestinal crypts regeneration in mice

*In - vivo system, based on*

**Cell lethality**







- Single fraction
- Irradiation to the whole body

- Tested beam**
- Clinical dose rate
  - Position depending on the type of beam






- Reference beam**
- Cobalt-60 or 7 MV
  - 1 Gy / min
  - Depth of the peak dose

# Reproducibility...

## Neutrons





## Protons




# Radiobiological characterization (protons)

Influence of depth







# 200 MeV protons NAC (Faure, South Africa)



# 200 MeV protons NAC (Faure) South Africa






# PSI



## Spot scanning

RBE =

1.11    1.16    1.21




Number of regenerated crypts per circumference




1 fract.



3 fract.






10 fract.



i = 4 h

Number of regenerated crypts  
per circumference



**Intestine (10 fractions)**



RBE (end) / RBE (middle)

**~ 1.08**


# Selective thoracic irradiation *in mice*

Irradiation in 10 fractions ( $i = 12$  h)

(middle vs end of the SOBP)




RBE relative to photons




RBE increases suddenly by 6 - 10° % from the **middle** to the **end** of the SOBPs

More precise irradiation is possible









# iThemba LABS (2006)

## 200 MeV protons, 7-cm SOBP




$$\frac{\text{RBE (end)}}{\text{RBE (middle)}} = \mathbf{1.10}$$


As an increase in RBE is observed at the end of the SOBP *in all biological systems*, it is **advisable to allow for it.**


**TPS** should include biological weighting functions


# Influence of fractionation (or dose)

# Crypt regeneration in mice


















Irradiation at the middle of a 7 cm SOBP  
 in the 200-MeV proton beam produced at the  
 National Accelerator Centre (NAC) of Faure (South Africa).

# *Late tolerance*

(Survival after selective irradiation  
of the thorax in mice)


**Proportion of surviving animal**




**Total absorbed dose /**

For both systems (10 fraction irradiations)  
RBE at the end of the SOBP ~ **6 % greater** that at the middle

Lung (10 fractions)




Intestine (10 fractions)




Proton RBE (at the middle of the SOBP) does not vary with dose (or fractionation) ***for in vivo systems***

A generic RBE value of **1.10** at the middle of the SOBP (i.e. point of dose specification) **seems to be appropriate**

## Proton RBE In-vitro, as a function of dose, for all "clinical" energies




## Proton RBE In-vivo, as a function of dose, for all "clinical" energies



# **HEAVY IONS**

↑  
LET

↑  
RBE




Quality of dose distribution →



# Salivary gland tumour treated with fast neutrons


## Study results ( $\pm$ 1985)

### local control



17%  $\pm$  11 vs. 67%  $\pm$  14

### survival




25%  $\pm$  14 vs. 62%  $\pm$  14

# Randomized clinical trial of photons vs mixed beam neutrons plus photons for prostate Ca


RTOG 77-04

Laramore *et al*, 1993.

Prostate carcinomas are slow growing and hence should be well suited for neutron therapy. The neutrons are usually used for the small “boost” volume in order to minimize late normal tissue damage.




# Neutron Prostate Study Major Complications



# CARBON COUNT

Around 12,000 patients worldwide have been treated at dedicated carbon-ion facilities in Europe, China and Japan. The construction of two new facilities, encouraging clinical-trial results and advances in the technology mean those numbers are likely to grow.



# Which RBE to apply ?


- Late tolerance of healthy surrounding tissues
- Dose per fraction of 2 Gy photon equivalent



**Not a single value**


- due to the diversity of the clinical situations
- due to variation of RBE with depth/dose

# Density of energy deposits in the Bragg peak of carbon ions




# Carbon ions

higher LET and variation in LET →



# Results

Set-up	Photons $D_{50}$ [Gy]	Carbon Ions $D_{50}$ [Gy]	Measured RBE
Plateau (13 keV/ $\mu$ m)			
1 Fx	24.5 $\pm$ 0.8	17.1 $\pm$ 0.8	1.43 $\pm$ 0.08
2 Fx	34.2 $\pm$ 0.7	24.9 $\pm$ 0.7	1.37 $\pm$ 0.05
6 Fx	57.0 $\pm$ 4.0	42.8 $\pm$ 1.5	1.33 $\pm$ 0.10
18 Fx	88.6 $\pm$ 2.0	62.2 $\pm$ 3.5	1.42 $\pm$ 0.09




Clear fractionation effect in the **plateau**, which allows sparing of normal tissues.

**RBE constant**, when number of fractions increase



# Results




Set-up	Photons D <sub>50</sub> [Gy]	Carbon Ions D <sub>50</sub> [Gy]	Measured RBE
Plateau (13 keV/μm)			
1 Fx	24.5±0.8	17.1±0.8	1.43±0.08
2 Fx	34.2±0.7	24.9±0.7	1.37±0.05
6 Fx	57.0±4.0	42.8±1.5	1.33±0.10
18 Fx	88.6±2.0	62.2±3.5	1.42±0.09

Peak (91 keV/μm)			
1 Fx	24.5±0.8	13.9±0.8	1.76±0.12
2 Fx	34.2±0.7	15.8±0.7	2.16±0.11
6 Fx	57.0±4.0	19.2±0.2	2.97±0.21
18 Fx	88.6±2.0	17.7±1.3	5.01±0.37

Effective response in the **Bragg-Peak**, with little change in isoeffective total dose with fractionation  
**RBE raises** rapidly with decreasing dose per fraction

HIMAC (Japan) : **Carbon-12**  
(290 MeV/uma)




Compensate the RBE increase by

**decreasing the physical dose**

by factors corresponding to the (local) RBE

Method used in static beam delivery systems (Chiba, Japan)




A given dose of carbon is biologically equivalent to the same dose of gamma multiplied by the carbon RBE


**Carbon dose x RBE**

Iso-doses (in Gy) in a given tissue do no longer correspond to iso-biologically effective doses !!!

Absorbed dose / Gy



Depth in water / mm



# LEM

***“Local effect Model”*** (Scholz et Kraft, 1994)

Derivation of parameters determining the biological response to a Carbon ion exposure from the response parameters to a photon irradiation

## Assumptions ●

*The biological effect in a cell nucleus sub-volume is **exclusively** determined by the energy deposit in this sub-volume*



*The biological effect is **independent** from the radiation quality of the beam*

## Consequences ●

A local dose deposit with Carbon ions produces the **same biological effect** than the same dose deposit with photons



Therefore, the different biological effects of Carbon ion and photons result from **differences in spatial dose deposition**

# Local Effect Model (LEM)

*(Scholz and Kraft)*

Parameters **exclusively** determined on the basis of :

- Dose-effect relationship **for photons** (low LET)

→ Probability of a letal event

- Physical data on **track structures**

→ Determination of local dose deposits

- **Experimental** measurement of cell nucleus size

→ Determination of radiosensitive area size  
(nucleus diameter)



## ***Advantages :***


- Conformational possibilities
- Possibility to treat sub-volumes
- Possibility of dose « modulation » within each volume of interest

• all RBE variation taken into account


## ***Inconvenients***

- Uncertainties on RBE calculation algorithm (LEM, other...)
- **Lack of transparency and total confidence in calculation model**
- Impossibility (*for the physician nor for the physicist*) to judge *directly* the appropriateness of treatments plans. Dose distributions have to be re-calculated with the model.


# Fractionated dose for clinical situation



# RBE of HSG and HeLa cells




# Carbon 290 MeV/u, 6c...P




8 mm apart from the distal edge

80 keV/μm


**Neutron clinical  
RBE = 3**



**RBE of HSG and Hela cells**



**Carbon clinical RBE at the  
center of the SOBP = 2.38**



## Raster scan system at GSI, Germany


*from : D. Schulz-Ertner, O. Jäkel, W. Schlegel*

*i.e. a system where :*

*“several thousands of narrow ion pencil beams with individual lateral positions, ion energies and particle fluences are combined to form an intensity-modulated field of high granularity”*

*(M. Krämer, 2001)*

Consideration of RBE variations is only possible in an integrated calculation code allowing iterative interaction between both physical and biological input parameters



An **RBE weighting factor** should be applied at **each point** of the irradiated volume, taking RBE variation with **energy, dose, biological system**, etc, into account


**Particules of variable energy** are also delivered at **variable dose rates** or in multi - *micro* fractions.

**Integrated algorithm** allowing for the **iterative interaction** between **physical** (e.g. energy/LET) and **biological parameters** (e.g. *intrinsic radiosensitivity, oxygenation, dose rates, micro-fractionation, etc.*)


# The “Inter-play” effect (Protons, PSI)

Under dosage

Over dosage




Dose heterogeneity  
~ 15% / mm





**Pitfalls...**



DR. SC. J. GUELETTE  
RADIOBIOLOGIE


Epidemia du 3 Decemb


Respiration


11 DEC. 1990

Free


Telling } 1 - 1000 Einheit } 90 mm  
 Logar. Division } 1 - 1000 Unité }  
 Nr. 534








**~ 1 % of the surface**



**~ 1 % of the surface**



Finally, which recommendation for irradiation schedule?

*Short hypofractionated schedules*

- Less tumour repopulation.
- More damage to quiescent cells.
- More microvascular damage.
- Differential release of cytokines and special immunologic effects?
- Too much assumptions in radiobiological models??